COSCIENS Biopharma Inc. (CSCI:TSX) closed at $8.60 on October 20, 2026, unchanged on the day. The stock trades 78.3% below its 52-week high of $39.60 and 22.9% above its 52-week low of $7.00. COSCIENS Biopharma Inc. is part of the Health Care sector.
In 252 trading sessions since October 20, 2025, CSCI closed higher on 104 days (41%). Its best day was January 12, 2026 (+764.47%) and its worst was July 3, 2026 (-65.04%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 9 times.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Find more stocks like CSCI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.